In a positive development, Larimar received Breakthrough Therapy Designation from the FDA for nomlabofusp, aimed at treating Friedreich's ataxia (FA). This designation underscores the potential of the drug to address significant unmet medical needs in this patient population. The company is on track to submit a Biologics License Application (BLA) seeking accelerated approval in June 2026, with topline data from an open-label study expected in Q2 2026. Furthermore, Larimar plans to initiate a global Phase 3 confirmatory study in mid-2026, which is a crucial step towards bringing this therapy to market.
The company successfully closed a public offering in February 2026, raising $115 million, which strengthens its balance sheet and extends its cash runway into the second quarter of 2027. As of December 31, 2025, Larimar reported $244.5 million in pro forma cash, cash equivalents, and marketable securities, reflecting a solid financial position to support its ongoing development efforts.
Overall, while the financial losses are notable, the receipt of Breakthrough Therapy Designation and the planned BLA submission are significant positive indicators for Larimar's future prospects. Investors may view these developments favorably, potentially leading to a modest positive effect on the stock price as the company advances its clinical programs.
